Rapid seizure resolution with cannabidiol in medically refractory epilepsy with myoclonic‐atonic seizures
Year: 2024
Type: article
Study design: Case Report
Abstract: Epilepsy with myoclonic-atonic seizures (EMAS) is an early childhood epilepsy syndrome with an explosive onset of multiple seizure types in a previously healthy child. EMAS often evolves to a drug-resistant epileptic encephalopathy before a variable degree of remission around 3 years from onset. Highly purified cannabidiol (CBD, available in United States as Epidiolex®) has demonstrated efficacy and tolerability as an adjunct in medically refractory EMAS. We present two cases of medically refractory EMAS achieving rapid seizure freedom (7-30 days) with CBD, illustrating CBD as a potential effective monotherapy in EMAS.
Source: Epileptic Disorders
DOI: 10.1002/epd2.20321
Authors: Peter F. Sarnacki, Elia Pestana‐Knight
Institution: Cleveland Clinic
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405107284